Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 8 | 2025 | 131 | 1.360 |
Why?
|
| Papillomavirus Infections | 5 | 2025 | 142 | 0.720 |
Why?
|
| Prevalence | 3 | 2018 | 840 | 0.620 |
Why?
|
| Electronic Health Records | 3 | 2020 | 704 | 0.570 |
Why?
|
| Confidentiality | 1 | 2018 | 25 | 0.570 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 72 | 0.570 |
Why?
|
| Statistics as Topic | 1 | 2018 | 56 | 0.560 |
Why?
|
| Papillomaviridae | 6 | 2025 | 61 | 0.560 |
Why?
|
| Primary Health Care | 3 | 2024 | 726 | 0.420 |
Why?
|
| Models, Statistical | 3 | 2019 | 170 | 0.400 |
Why?
|
| Early Detection of Cancer | 4 | 2025 | 529 | 0.380 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 173 | 0.360 |
Why?
|
| Cervical Intraepithelial Neoplasia | 3 | 2022 | 16 | 0.350 |
Why?
|
| Humans | 21 | 2025 | 17314 | 0.300 |
Why?
|
| Female | 19 | 2025 | 12396 | 0.290 |
Why?
|
| Incidence | 4 | 2020 | 1266 | 0.290 |
Why?
|
| Colposcopy | 2 | 2025 | 6 | 0.270 |
Why?
|
| Smoking | 3 | 2020 | 429 | 0.250 |
Why?
|
| Risk Assessment | 3 | 2019 | 1076 | 0.240 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2025 | 10 | 0.240 |
Why?
|
| Middle Aged | 14 | 2024 | 7836 | 0.230 |
Why?
|
| Adult | 12 | 2025 | 7500 | 0.220 |
Why?
|
| Aged | 12 | 2024 | 6084 | 0.210 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 114 | 0.210 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 13 | 0.190 |
Why?
|
| Borrelia burgdorferi | 1 | 2020 | 1 | 0.170 |
Why?
|
| Lyme Disease | 1 | 2020 | 4 | 0.170 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 13 | 0.170 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 384 | 0.170 |
Why?
|
| Telephone | 1 | 2021 | 150 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 31 | 0.170 |
Why?
|
| Patient Participation | 1 | 2021 | 119 | 0.170 |
Why?
|
| Prognosis | 2 | 2019 | 603 | 0.170 |
Why?
|
| Likelihood Functions | 1 | 2020 | 45 | 0.170 |
Why?
|
| Cancer Survivors | 1 | 2020 | 101 | 0.150 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 17 | 0.150 |
Why?
|
| Mass Screening | 3 | 2022 | 672 | 0.150 |
Why?
|
| Gastrectomy | 1 | 2018 | 47 | 0.150 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2018 | 5 | 0.150 |
Why?
|
| Telemedicine | 1 | 2021 | 181 | 0.140 |
Why?
|
| Sampling Studies | 1 | 2018 | 43 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 42 | 0.140 |
Why?
|
| Inpatients | 1 | 2018 | 79 | 0.140 |
Why?
|
| Male | 9 | 2024 | 9804 | 0.140 |
Why?
|
| Biomarkers | 2 | 2019 | 307 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2018 | 86 | 0.140 |
Why?
|
| Logistic Models | 2 | 2017 | 879 | 0.140 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 22 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 47 | 0.140 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 43 | 0.140 |
Why?
|
| Health Surveys | 1 | 2018 | 245 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2017 | 51 | 0.130 |
Why?
|
| United States | 6 | 2025 | 3866 | 0.130 |
Why?
|
| Occupations | 1 | 2016 | 15 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2017 | 202 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 153 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2017 | 52 | 0.130 |
Why?
|
| Occupational Exposure | 1 | 2016 | 67 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 57 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 1925 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2016 | 41 | 0.120 |
Why?
|
| Algorithms | 1 | 2017 | 223 | 0.120 |
Why?
|
| Lung | 1 | 2016 | 60 | 0.120 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 3 | 0.110 |
Why?
|
| Indians, North American | 1 | 2014 | 48 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 7 | 0.110 |
Why?
|
| Vaginal Smears | 3 | 2022 | 47 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 243 | 0.110 |
Why?
|
| Opiate Substitution Treatment | 2 | 2024 | 45 | 0.110 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 476 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1280 | 0.100 |
Why?
|
| Mammography | 1 | 2014 | 168 | 0.100 |
Why?
|
| African Americans | 1 | 2016 | 439 | 0.100 |
Why?
|
| Heart Failure | 1 | 2017 | 401 | 0.090 |
Why?
|
| Risk Factors | 5 | 2017 | 3258 | 0.090 |
Why?
|
| Young Adult | 2 | 2025 | 2465 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 664 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2008 | 74 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2008 | 92 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 298 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 969 | 0.060 |
Why?
|
| Triage | 2 | 2016 | 19 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2025 | 2415 | 0.060 |
Why?
|
| Nursing Care | 1 | 2024 | 4 | 0.060 |
Why?
|
| Probability | 2 | 2019 | 71 | 0.060 |
Why?
|
| Massachusetts | 1 | 2024 | 60 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 342 | 0.060 |
Why?
|
| Buprenorphine | 1 | 2024 | 48 | 0.050 |
Why?
|
| Videoconferencing | 1 | 2021 | 7 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 25 | 0.050 |
Why?
|
| California | 2 | 2017 | 2311 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 1 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2020 | 3 | 0.040 |
Why?
|
| Gene Library | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2514 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 92 | 0.040 |
Why?
|
| Mice | 1 | 2020 | 80 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 381 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 132 | 0.040 |
Why?
|
| Vaccination | 1 | 2025 | 688 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 280 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 496 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 5 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 80 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 804 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2018 | 131 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 223 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 8 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2017 | 37 | 0.030 |
Why?
|
| Creatinine | 1 | 2017 | 66 | 0.030 |
Why?
|
| Kidney | 1 | 2017 | 52 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 92 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 82 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 226 | 0.030 |
Why?
|
| Adolescent | 1 | 2024 | 3538 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2016 | 70 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 66 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 1 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 7 | 0.030 |
Why?
|
| Metabolomics | 1 | 2014 | 8 | 0.030 |
Why?
|
| Isoflavones | 1 | 2014 | 14 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 46 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 5 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 14 | 0.030 |
Why?
|
| Obesity | 1 | 2020 | 814 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 128 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 603 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 674 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 878 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1151 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 1226 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 9 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2008 | 51 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 270 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 535 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 1282 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2008 | 937 | 0.010 |
Why?
|
Concepts
(141)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->